The Immune Response to Tumors

Michael Dougan1, Glenn Dranoff1

1 Department of Medical Oncology and Cancer Vaccine Center, Dana‐Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Publication Name:  Current Protocols in Immunology
Unit Number:  Unit 20.11
DOI:  10.1002/0471142735.im2011s85
Online Posting Date:  April, 2009
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

The immune response to tumors is complex. Cells of the immune system can inhibit tumor growth and progression through the recognition and rejection of malignant cells, a process referred to as immunoediting. Yet, immune responses can also promote tumor cell growth, survival, and angiogenesis through the induction of oncogenic inflammation. Immunodeficiency can predispose to the development of spontaneous and virally induced cancer, and established tumors often generate immunosuppressive microenvironments that can block productive antitumor immunity, serving as a substantial barrier to effective immune therapy. Through a deeper understanding of the complicated relationship between tumors and the immune system, tumor immunology strives to harness the immune system to generate protective antitumor responses in patients. Curr. Protoc. Immunol. 85:20.11.1‐20.11.4. © 2009 by John Wiley & Sons, Inc.

Keywords: cancer; immunoediting; immunotherapy; immunosuppression; inflammation; antitumor immunity

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Immunoediting and Spontaneous Antitumor Immunity
  • Immunosuppression in the Tumor Microenvironment
  • Tumor Promotion by Chronic Inflammation
  • Therapeutic Induction of Antitumor Immunity
  • Literature Cited
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
   Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., and Freeman, G.J. 2007. Programmed death‐1 ligand 1 interacts specifically with the B7‐1 costimulatory molecule to inhibit T cell responses. Immunity 27:111‐122.
   Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S., and Vignali, D.A. 2007. The inhibitory cytokine IL‐35 contributes to regulatory T‐cell function. Nature 450:566‐569.
   Curiel, T.J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117:1167‐1174.
   Dougan, M. and Dranoff, G. 2008. Immune therapy for cancer. Annu. Rev. Immunol. 2008 Nov 13. Epub ahead of print.
   Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329‐360.
   El‐Omar, E.M., Carrington, M., Chow, W.H., McColl, K.E., Bream, J.H., Young, H.A., Herrara, J., Lissowska, J., Yuan, C.C., Rothman, N., Lanyon, G., Margin, M., Fraumeni, J.F., Jr., and Rabkin, C.S. 2000. Interleukin‐1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398‐402.
   Galon, J., Costes, A., Sanchez‐Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce‐Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoue, F., Bruneval, P., Cugnenc, P.H., Trajanoski, Z., Fridman, W.H., and Pages, F. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960‐1964.
   Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Dagnoff, M.F., and Karin, M. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis‐associated cancer. Cell 118:285‐296.
   Karin, M. and Greten, F.R. 2005. NF‐kappaB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5:749‐759.
   Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., and Schreiber, R.D. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903‐907.
   Lin, W.W. and Karin, M. 2007. A cytokine‐mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117:1175‐1183.
   Munn, D.H. and Mellor, A.L. 2007. Indoleamine 2,3‐dioxygenase and tumor‐induced tolerance. J. Clin. Invest. 117:1147‐1154.
   Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M., and Karin, M. 2007. Gender disparity in liver cancer due to sex differences in MyD88‐dependent IL‐6 production. Science 317:121‐124.
   Rakoff‐Nahoum, S. and Medzhitov, R. 2007. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124‐127.
   Sica, A. and Bronte, V. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117:1155‐1166.
   Swann, J.B. and Smyth, M.J. 2007. Immune surveillance of tumors. J. Clin. Invest. 117:1137‐1146.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library